康臣藥業(01681.HK)上半年純利增18.4%至2.97億元 持續致力開拓產品市場
格隆匯8月26日丨康臣藥業(01681.HK)公佈中期業績,截至2022年6月30日止六個月,收入為人民幣9.94億元,較截至2021年6月30日止六個月增加約12.1%;公司權益股東應占溢利為人民幣2.97億元,較截至2021年6月30日止六個月增加約18.4%;每股基本及攤薄盈利分別約為人民幣0.3743元及人民幣0.3733元。
按產品系列分類,腎科系列產品銷售較去年同期錄得增長達14.0%,其中尿毒清顆粒仍然是集團的皇牌產品,維持市場領先地位;醫用成像對比劑銷售較去年同期增長達12.8%,仍然穩佔國內磁共振成像對比劑市場的前列;骨傷系列產品銷售較去年同期增長約202.9%;皮膚系列產品銷售較去年同期增長約17.4%;肝膽系列產品銷售較去年同期下降73.5%;婦幼系列產品銷售較去年同期增長1.3%;其他藥物銷售較去年同期下降24.6%。整體銷售收入的增加主要是由於集團持續致力開拓產品市場以及發展全國各地的銷售網絡所致。
展望下半年,公司將進一步提升銷售團隊人員質素和銷售能力,擴大服務醫院及患者覆蓋面,促進上量;繼續加大研發投入,保證在研新藥項目按期推進,並不斷探索產品創新領域;提升格局,保持定力,將集團內部的事情做好,積極應對內外環境變化,爭取用全年業績增長的優秀呈現,回報廣大投資者的認同與支持。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.